Ocular Surface Disease

Here’s why formulation matters.

Collaboration between ophthalmologists, optometrists can boost early detection.

Tracy Doll, OD, FAAO, shares an overview of her anterior segment symposium presented during the 2023 AAOpt annual meeting.

Private practice eye care providers’ ability to immediately administer antibiotic eye drops or have them overnighted to the patient is a giant step forward for practice and patient.

Therapies and technologies to treat allergic conjunctivitis are rapidly changing.

Hear what is new in the world of ocular surface disease, and what's coming down the pipeline.

Results of the BRIO-I study, the first of 2 phase 3 clinical trials of Brimochol PF, a topical, fixed-dose combination for the treatment of presbyopia, have recently been released.

Ben Bergo, CEO of Visus, shares data from the company's pivotal phase 3 BRIO-1 trial, as well as answers questions about Brimochol PF.

Easy-to-use modality offers exciting benefits for patients.

Combination therapy may reduce adverse events related to corticosteroids alone.

Set your young patients—and their caregivers—up for success in treatment.

According to Bausch + Lomb, MIEBO (perfluorohexyloctane ophthalmic solution) is the first prescription eye drop that targets tear evaporation.

Dual-purpose therapeutics help patients with both conditions.

The organization says to stop using Dr. Berne’s and LightEyez MSM drops immediately due to bacterial contamination, fungal contamination, or both.

This NDA transfer marks the fourth FDA-approved ophthalmic product purchased by Harrow earlier in 2023 now commercially available in the US.

Pediatric keratoconus is often more challenging to diagnose, resulting in treatment delay and vision loss.

Combining simple and advanced methods can lead to optimal patient outcomes.

Proper management results in better expectations, outcomes for patients.

The company has entered a definitive agreement with Novartis to acquire Xiidra (liftegrast ophthalmic solution 5%), representing a significant opportunity for growth in prescription dry eye.

Horizon Therapeutics announced the Brazilian Health Regulatory Agency (ANVISA) has approved TEPEZZA as the first and only medicine approved in Brazil for treatment of thyroid eye disease.

The evolution opens doors for the treatment of neurotrophic keratitis and beyond.

Mydcombi is the first FDA-approved, fixed-combination of tropicamide and phenylephrine for the reversal of mydriasis.

Selina McGee, OD, FAAO, Dipl ABO, shares highlights from her featured symposium, "Thyroid eye disease: The masquerading eye disorder," which she co-presented during the 2023 Controversies in Modern Eye Care meeting.

Laura Periman, MD, breaks down some myths and controversies in the cosmetic world in her presentation, "Ocular toxins everywhere and in everything," presented at the Controversies in Modern Eye Care meeting.

Several eye conditions may benefit from membrane application.